Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.

Related News Articles

Headline
AHA Feb. 26 submitted comments on the Centers for Medicare & Medicaid Services’ proposed rule establishing appeals rights for Medicare beneficiaries…
Headline
Physicians and other practitioners who provided evaluation and management (E/M) services via telehealth during the first nine months of the COVID-19 public…
Headline
The Centers for Medicare & Medicaid Services has released financial specifications for the hospital global budget methodology for Medicare fee-for-service…
Perspective
Two presidents that America honors with a federal holiday on Monday shared a number of memorable traits. George Washington and Abraham Lincoln were blessed…
Chairperson's File
The mission of all hospitals and health systems, regardless of size and location, is to provide quality care to patients and advance health in their…
Perspective
For the 61 million Americans who live in rural areas, their hospital is the lifeblood of the community. Often, it is the only source of emergency, preventive…